Drug Trial Radar · NCT00313716
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Last checked: Nov 19, 2026Latest source record: Sep 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Apr 2006
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Claudia Sue RobertsonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Apr 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.
Conditions
- Anemia
- Traumatic Brain Injury
Interventions
recombinant human erythropoietin, rhEpoDrug
The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
placeboOther
an inactive substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glasgow Outcome ScaleTime frame: at 6 months after injury
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Baylor College of Medicine, Ben Taub General Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.